KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovoCure (NVCR) Debt to Equity (2016 - 2026)

NovoCure's Debt to Equity history spans 12 years, with the latest figure at $0.59 for Q1 2026.

  • On a quarterly basis, Debt to Equity rose 119.52% to $0.59 in Q1 2026 year-over-year; TTM through Mar 2026 was $0.59, a 119.52% increase, with the full-year FY2025 number at $0.57, up 112.07% from a year prior.
  • Debt to Equity hit $0.59 in Q1 2026 for NovoCure, up from $0.57 in the prior quarter.
  • Over the last five years, Debt to Equity for NVCR hit a ceiling of $1.59 in Q1 2024 and a floor of $0.27 in Q2 2024.
  • Historically, Debt to Equity has averaged $0.87 across 5 years, with a median of $0.93 in 2022.
  • Biggest five-year swings in Debt to Equity: crashed 83.02% in 2025 and later surged 119.52% in 2026.
  • Tracing NVCR's Debt to Equity over 5 years: stood at $1.28 in 2022, then grew by 12.55% to $1.44 in 2023, then plummeted by 81.27% to $0.27 in 2024, then skyrocketed by 112.07% to $0.57 in 2025, then increased by 3.17% to $0.59 in 2026.
  • Business Quant data shows Debt to Equity for NVCR at $0.59 in Q1 2026, $0.57 in Q4 2025, and $0.57 in Q3 2025.